Clinical trials on CBD-based medical drug Epidiolex missed their main goal of registering a significant reduction in the frequency of seizures experienced by patients in Japan, based on the results reported by manufacturer Jazz Pharmaceuticals.
The company, which just released the outcome of its recently concluded phase 3 clinical trials on Epidiolex in Japan, said that, while its primary objective was not achieved, the tests showed different improvements and did not highlight any unknown safety concerns over the drug.
Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
"*" indicates required fields
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
LATEST ALERTS
